AMP 2024 Annual Meeting & Expo

Register for AMP 2024 to attend sessions sponsored by Illumina.

AMP is the primary resource for expertise, education, and collaboration in the field of molecular pathology. AMP members influence policy and regulation on national and international levels, ultimately serving to advance innovation in the field and protect patient access to high-quality appropriate testing.

Join us at Booth #1107 to learn how Illumina is transforming oncology with genomics through our expanded TruSight™ portfolio and end-to-end workflow of solutions.

____________________________________________________________________________________________________________

Wednesday, November 20 | 11:00 AM – 1:50 PM (PT)

Illumina Corporate Workshops

A panel discussion on challenges and practice gaps affecting implementation of oncology precision medicine.
11:00 AM – 11:50 AM (PT)
Room 212 & 213, Level 2
Co-hosted by Bayer

Though biomarker testing is now considered standard of care for therapeutic decision making in cancer care, real-world evidence has identified several practice gaps, resulting in many patients not receiving biomarker testing results and/or matched targeted therapies.

The audience will take part in a discussion with an expert panel of two pathologists and an oncologist on:

• Challenges and practice gaps identified in precision medicine implementation
• Coordination of a multidisciplinary team to ensure optimal biomarker detection and targeted therapy utilization, leading to more favorable patient outcomes

Nikoletta Sidiropoulos, MD
Associate Professor, Department of Pathology and Laboratory Medicine
University of Vermont Medical Center

Thomas Stricker, MD, PhD
Senior Medical Director of Precision Medicine
OneOncology

Heidi Ko, DO
Medical Director, Medical Affair
Labcorp Oncology

Clinical scenarios demonstrating value of NGS using rapid, targeted panel and/or comprehensive approaches for oncology biomarker testing of tissue and liquid specimens.
12:00 PM – 12:50 PM (PT)
Room 212 & 213, Level 2

When choosing the optimal NGS approach for biomarker testing, there are a wide variety of factors to consider for successful delivery of results. The optimal specimen type (tissue and plasma) and sequencing approach (rapid targeted panel and comprehensive) needs to be considered for each patient case across cancer types. The audience will participate in a discussion with an expert on clinical scenarios that can impact NGS success rate and selection of the best specimen and NGS approach including:

• Limited tissue or DNA/RNA input
• Aggressiveness of patient’s disease
• Determining clinical trial eligibility
• Detection of gene signatures (i.e. TMB) & rare variants

Karina Eterovic, MSc, PhD
Director, Oncology Diagnostics R&D
Eurofins-Viracor Clinical Diagnostics

Practical considerations for integrating enterprise-wide Pharmacogenomics (PGx)
1:00 PM – 1:50 PM (PT)
Room 212 & 213, Level 2

The growing evidence of pharmacogenomics across many clinical applications (oncology, cardiology, pain management) and the value-based care it offers has made its utility palatable across the healthcare industry. However, the lack of policy expansion or access and turnkey technology solutions has restricted adoption and utilization.

Atrium Health has researched and developed an integration model for enterprise wide PGx testing in a community-academic hybrid setting, developed in part with Illumina array technology. The considerations presented will likely guide labs and healthcare organizations with their approach to support PGx integration across service lines and align with system strategic goals and initiatives.

Jai N. Patel, PharmD, CPP
Director, Cancer Pharmacology & Pharmacogenomics
Associate VP Research, Atrium Health Levine Cancer

____________________________________________________________________________________________________________

Thursday, November 21 | 12:00 PM - 12:30 PM (PT)

Innovation Spotlight Session

TruSight Oncology Portfolio IVD and RUO Expansion
12:00 PM – 12:30 PM (PT)
Theater Exhibit: Stage #1

As utilization of comprehensive genomic profiling (CGP) of solid tumors grows, more distributed kit options are expanding access to NGS-based biomarker profiling. Hear from Illumina experts on recent developments and future expansions to the TruSight Oncology portfolio, including our recently FDA-approved TruSight Oncology Comprehensive.

Heather Robinson
Staff Product Manager
Illumina, Inc.

Samyuktha Dasari
Staff Product Manager
Illumina, Inc.

__________________________________________________________________________________________

Friday, November 22 | 9:30 AM - 10:00 AM (PT)

Innovation Spotlight Session

Illumina MiSeq i100 Benchtop Sequencer Innovation
9:30 AM – 10:00 AM (PT)
Theater Exhibit: Stage #2

Unlock the power of next-generation sequencing (NGS) with Illumina's innovative new MiSeq i100 Plus system. This advanced device offers a flexible, accessible design that simplifies use for novices while enhancing workflows and reducing sequencing times. Join us to explore how these cutting-edge innovations ensure high-quality data, driving better discoveries in your research. Don't miss the opportunity to learn about the latest advancements in benchtop sequencing technology!

Emmanuel Naouri
Associate Director, Product Management
Illumina, Inc.

__________________________________________________________________________________________

Exhibit Hours
Illumina booth #1107

Thursday, November 21

11:15 AM – 7:00 PM (PT)

Friday, November 22

9:00 AM – 4:00 PM (PT)

Saturday, November 23

9:00 AM – 1:30 PM (PT)